Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Han, Zhigang
NCT04740021: Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer	Recruiting	2	46	RoW	LP002, Carboplatin, Etoposide	Taizhou HoudeAoke Biomedical Co., Ltd.	Small-cell Lung Cancer	02/22	08/22
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA	Recruiting	2	280	RoW	Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab	Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.	Non-small Cell Lung Cancer	02/25	02/28